These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 27334457)
41. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018. Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908 [TBL] [Abstract][Full Text] [Related]
42. Deterministic models for the eradication of poliomyelitis: vaccination with the inactivated (IPV) and attenuated (OPV) polio virus vaccine. Eichner M; Hadeler KP Math Biosci; 1995 Jun; 127(2):149-66. PubMed ID: 7795316 [TBL] [Abstract][Full Text] [Related]
43. Progress toward poliomyelitis eradication--India, January 2007-May 2009. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2009 Jul; 58(26):719-23. PubMed ID: 19590492 [TBL] [Abstract][Full Text] [Related]
44. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. Kalkowska DA; Duintjer Tebbens RJ; Thompson KM J Infect Dis; 2014 Nov; 210 Suppl 1():S412-23. PubMed ID: 25316863 [TBL] [Abstract][Full Text] [Related]
49. Silent reintroduction of wild-type poliovirus to Israel, 2013 - risk communication challenges in an argumentative atmosphere. Kaliner E; Moran-Gilad J; Grotto I; Somekh E; Kopel E; Gdalevich M; Shimron E; Amikam Y; Leventhal A; Lev B; Gamzu R Euro Surveill; 2014 Feb; 19(7):20703. PubMed ID: 24576475 [TBL] [Abstract][Full Text] [Related]
50. The cost-effectiveness of alternative polio immunization policies in South Africa. Griffiths UK; Botham L; Schoub BD Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096 [TBL] [Abstract][Full Text] [Related]
51. Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status. John TJ; Vashishtha VM Indian J Med Res; 2013 May; 137(5):881-94. PubMed ID: 23760372 [TBL] [Abstract][Full Text] [Related]
57. The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting. Mangal TD; Aylward RB; Grassly NC Am J Epidemiol; 2013 Nov; 178(10):1579-87. PubMed ID: 24100955 [TBL] [Abstract][Full Text] [Related]
58. [Poliomyelitis--why we must continue to vaccinate!]. Windorfer A; Beyrer K MMW Fortschr Med; 2005 Feb; 147(8):36, 38, 40. PubMed ID: 18437859 [TBL] [Abstract][Full Text] [Related]
59. Progress toward poliomyelitis eradication---India, January 2010--September 2011. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1482-6. PubMed ID: 22048729 [TBL] [Abstract][Full Text] [Related]
60. A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people. Kim HJ; Hwang S; Lee S; Kwon Y; Park K; Park YJ; Bae GR; Lee SW; Jeong YS; Hyeon JY BMC Infect Dis; 2015 Mar; 15():164. PubMed ID: 25881203 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]